ARTICLE | Company News
HistoRx, Yale University deal
January 2, 2012 8:00 AM UTC
The university granted HistoRx rights to an assay that identifies melanoma patients who have a 40% risk of recurrence of the disease despite having no detectable cancer in their lymph nodes. The assay...